Escherichia coli Nissle 1917 (EcN) is a probiotic used for the treatment of intestinal disorders. EcN improves gastrointestinal homeostasis and microbiota balance; however, little is known about how this probiotic delivers effector molecules to the host.

Benefiting from its good biocompatibility and ideal targeting ability as a biological carrier, Escherichia coli Nissle 1917 (ECN) has been focused on the treatment strategies of inflammatory bowel disease and tumor. The advantage of a bacterial carrier is that it can express exogenous protein while also acting as a natural capsule by releasing

Escherichia coli Nissle 1917 (EcN) is an intestinal probiotic that is effective for the treatment of intestinal disorders, such as inflammatory bowel disease and ulcerative colitis. EcN is a representative Gram-negative probiotic in biomedical research and is an intensively studied probiotic. However, to date, its genome-wide metabolic network model has not been developed. Here, we developed a
In the present study, we investigated effects of prebiotic fructooligosaccharides (FOS) on the ability of Escherichia coli Nissle 1917 (EcN), a probiotic bacterial strain, to adhere to co-cultures of human intestinal cells (Caco-2 and HT29-MTX). For the bacterial adhesion assay, the co-cultures were seeded together at a ratio of 3:1 and then incubated EcN in the presence of various prebiotics
Investigators at Massachusetts General Hospital (MGH), a founding member of Mass General Brigham (MGB), have engineered a strain of the probiotic Escherichia coli (E. coli), Nissle 1917, to

The aim of the present study was to correlate the intestinal anti-inflammatory activity of the probiotic Escherichia coli Nissle 1917 (EcN) in the dextran sodium sulfate (DSS) model of mouse colitis with the changes induced in colonic microbiota populations. EcN prevented the DSS-induced colonic damage, as evidenced by lower disease activity

As an approach to the lowering of blood ammonia arising from the intestine, we engineered the orally delivered probiotic Escherichia coli Nissle 1917 to create strain SYNB1020 that converts NH 3 to l-arginine (l-arg).
Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat certain gastrointestinal disorders. It is fast emerging as an important target for the development of therapeutic engineered bacteria, benefiting from the wealth of knowledge of E. coli biology and ease of manipulation. Bacterial synthetic biology projects commonly utilize engineered plasmid vectors, which
10.1128/JB.186.16.5432-5441.2004. Nonpathogenic Escherichia coli strain Nissle 1917 (O6:K5:H1) is used as a probiotic agent in medicine, mainly for the treatment of various gastroenterological diseases. To gain insight on the genetic level into its properties of colonization and commensalism, this strain's genome structure has been analyzed by We investigated, in chicks, the anti-S. Enteritidis effects of Escherichia coli (E. coli) Nissle 1917, the most well-known probiotic member of Enterobacteriaceae. Eighty 1-d-old healthy female AA broilers were randomly divided into 4 groups, with 20 in each group, namely the negative control (group P), the E. coli Nissle 1917-treated group CCK-8 assay, Hoechst 33258 staining and flow cytometry analysis were used for examining cytotoxicity of tumoricidal protein azurin toward CT26 cells. An engineered probiotic Ep-AH harboring azurin and hlpA genes was developed using Escherichia coli Nissle 1917 (EcN) chassis. Antitumor effects of Ep-AH were evaluated in the azoxymethane (AOM The non-genotoxic E. coli Nissle 1917 mutant exacerbates the mortality of colitic mice. We next examined the probiotic properties of the non-genotoxic E. coli Nissle 1917 mutant in a T-cell dependent model of chronic colitis induced by the adoptive transfer of naïve CD4 + CD45RB high T cells in immunocompromised SCID Escherichia coli strain Nissle has been used as a probiotic and therapeutic agent for over a century. Reports suggest that Nissle protects mice from enterohemorrhagic E. coli (EHEC) O157:H7 strains; however, mice are not very susceptible to O157:H7 and are not accurate models for O157: … Escherichia coli Nissle 1917 (EcN) is commonly used as a treatment for human diseases due to its probiotic characteristics and robustness in the gastrointestinal tract. Sufficient genetic manipulation tools are suitable for EcN engineering, making it be the most widely used chassis for biomedical applications. 4UcR6Z.
  • n0c23vjysf.pages.dev/280
  • n0c23vjysf.pages.dev/393
  • n0c23vjysf.pages.dev/222
  • n0c23vjysf.pages.dev/438
  • n0c23vjysf.pages.dev/232
  • n0c23vjysf.pages.dev/410
  • n0c23vjysf.pages.dev/443
  • n0c23vjysf.pages.dev/423

    • e coli nissle 1917 probiotic